Latham & Watkins Advises Underwriters in Chimerix’ Public Offering of Common Stock

Capital markets team represented the underwriters in the offering by the biopharmaceutical company.

January 21, 2021

Chimerix, Inc., a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, has announced the pricing of its underwritten public offering of 11,765,000 shares of its common stock at a price to the public of US$8.50 per share. All of the shares to be sold in the offering are being sold by Chimerix. The gross proceeds to Chimerix from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be US$100 million. In addition, Chimerix has granted the underwriters a 30-day option to purchase up to an additional 1,764,750 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about January 25, 2021.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by New York partner Nathan Ajiashvili and San Diego partner Michael Sullivan, with associates Denis Griffin, Christopher West, and Shelby Harrison.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.